Education
About Us
Working with TipRanks
Follow Us
Cabaletta Bio, Inc. (CABA)
:CABA
CABA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.16 - $19.04
Previous CloseN/A
Volume846.62K
Average Volume (3M)1.08M
Market Cap
$67.69M
Enterprise Value-$34.41M
Total Cash (Recent Filing)-$1.00K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta3.47
Next Earnings
May 14, 2025EPS Estimate
-0.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.33
Shares Outstanding50,743,100
10 Day Avg. Volume927,584
30 Day Avg. Volume1,081,170
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.51
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit24.13
Enterprise Value/Ebitda0.30
Forecast
1Y Price Target
$15.75Price Target Upside1041.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Cabaletta Bio News
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressUpdated clinical data from the first 10 patients dosed in the RESET trials showed robust benefit in Lupus and dermatomyositis.
Enrollment And Trial ExpansionRapid enrollment continues across the CABA-201 RESET clinical program with 56 sites now active.
Regulatory EngagementCabaletta anticipates meeting with the FDA to discuss the design of a potential registrational trial of rese-cel.
Bears Say
Protocol ViolationsA significant protocol violation occurred when a patient reported a fever three days prior to rese-cel infusion but this was not disclosed to the trial’s medical monitor.
Safety ConcernsThe new case of high-grade ICANS with rese-cel highlights the complexity of treatment and could limit its commercial adoption.
Treatment ComplexityThe scrutiny required to mitigate CRS/ICANS may impact the rate of adoption of rese-cel once it becomes commercial.
---
Ownership Overview
5.84%
Insiders
23.93% Mutual Funds
36.94% Other Institutional Investors
24.40% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CABA FAQ
What was Cabaletta Bio, Inc.’s price range in the past 12 months?
Cabaletta Bio, Inc. lowest stock price was $1.16 and its highest was $19.04 in the past 12 months.
What is Cabaletta Bio, Inc.’s market cap?
Cabaletta Bio, Inc.’s market cap is $67.69M.
When is Cabaletta Bio, Inc.’s upcoming earnings report date?
Cabaletta Bio, Inc.’s upcoming earnings report date is May 14, 2025 which is in 42 days.
How were Cabaletta Bio, Inc.’s earnings last quarter?
Cabaletta Bio, Inc. released its earnings results on Mar 31, 2025. The company reported -$0.65 earnings per share for the quarter, beating the consensus estimate of -$0.655 by $0.005.
Is Cabaletta Bio, Inc. overvalued?
According to Wall Street analysts Cabaletta Bio, Inc.’s price is currently Undervalued.
Does Cabaletta Bio, Inc. pay dividends?
Cabaletta Bio, Inc. does not currently pay dividends.
What is Cabaletta Bio, Inc.’s EPS estimate?
Cabaletta Bio, Inc.’s EPS estimate is -0.64.
How many shares outstanding does Cabaletta Bio, Inc. have?
Cabaletta Bio, Inc. has 50,743,100 shares outstanding.
What happened to Cabaletta Bio, Inc.’s price movement after its last earnings report?
Cabaletta Bio, Inc. reported an EPS of -$0.65 in its last earnings report, beating expectations of -$0.655. Following the earnings report the stock price went down -10.968%.
Which hedge fund is a major shareholder of Cabaletta Bio, Inc.?
Currently, no hedge funds are holding shares in CABA
---
Cabaletta Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.75 (1041.30% Upside)
$15.75 (1041.30% Upside)
Blogger Sentiment
Neutral
CABA Sentiment 50%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 23.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days >0.1%
Last 30 Days ▼ 0.5%
Last 30 Days ▼ 0.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-93.04%
12-Months-Change
Fundamentals
Return on Equity
-59.64%
Trailing 12-Months
Asset Growth
-25.49%
Trailing 12-Months
Company Description
Cabaletta Bio, Inc.
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
---
CABA Stock 12 Month Forecast
Average Price Target
$15.75
▲(1041.30% Upside)
Technical Analysis
MacroGenics
―
Fate Therapeutics
―
Adaptimmune Therapeutics
―
Precision BioSciences
―
Kalaris Therapeutics
―
Best Analysts Covering CABA
1 Year
1 Year Success Rate
10/21 ratings generated profit
1 Year Average Return
+170.88%
reiterated a buy rating 2 days ago
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 47.62% of your transactions generating a profit, with an average return of +170.88% per trade.
---